These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 12575622

  • 41. Use of Palivizumab for prevention of hospitalization as a result of respiratory syncytial virus in infants with cystic fibrosis.
    Speer ME, Fernandes CJ, Boron M, Groothuis JR.
    Pediatr Infect Dis J; 2008 Jun; 27(6):559-61. PubMed ID: 18434935
    [Abstract] [Full Text] [Related]

  • 42. Passive immunisation of preterm infants with palivizumab against RSV infection.
    Harkensee C, Brodlie M, Embleton ND, Mckean M.
    J Infect; 2006 Jan; 52(1):2-8. PubMed ID: 16236360
    [Abstract] [Full Text] [Related]

  • 43. Populations at risk for developing respiratory syncytial virus and risk factors for respiratory syncytial virus severity: infants with predisposing conditions.
    Weisman L.
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S33-7; discussion S37-9. PubMed ID: 12671450
    [Abstract] [Full Text] [Related]

  • 44. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis.
    Giebels K, Marcotte JE, Podoba J, Rousseau C, Denis MH, Fauvel V, Laberge S.
    Pediatr Pulmonol; 2008 Feb; 43(2):169-74. PubMed ID: 18085710
    [Abstract] [Full Text] [Related]

  • 45. Prophylaxis with palivizumab against respiratory syncytial virus infection in infants with congenital heart disease--who should receive it?
    Sunnegårdh J.
    Acta Paediatr; 2006 Apr; 95(4):388-90. PubMed ID: 16720482
    [Abstract] [Full Text] [Related]

  • 46. [Current news about epidemiology of syncytial respiratory virus infection].
    Palumbo E.
    Recenti Prog Med; 2008 May; 99(5):237-9. PubMed ID: 18581965
    [Abstract] [Full Text] [Related]

  • 47. Readmission with respiratory syncytial virus (RSV) infection among graduates from a neonatal intensive care unit.
    McCormick J, Tubman R.
    Pediatr Pulmonol; 2002 Oct; 34(4):262-6. PubMed ID: 12205567
    [Abstract] [Full Text] [Related]

  • 48. [Chemoprophylaxis with palivizumab in Andalusia (Spain). Results of the 2000-2001 respiratory syncytial virus epidemic].
    Grupo de Hospitales Benazuza.
    An Esp Pediatr; 2002 Apr; 56(4):293-7. PubMed ID: 11927095
    [Abstract] [Full Text] [Related]

  • 49. Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit?
    Geskey JM, Ceneviva GD, Brummel GL, Graff GR, Javier MC.
    Clin Ther; 2004 Dec; 26(12):2130-7. PubMed ID: 15823776
    [Abstract] [Full Text] [Related]

  • 50. Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry.
    Frogel M, Nerwen C, Boron M, Cohen A, VanVeldhuisen P, Harrington M, Groothuis J, Palivizumab Outcomes Registry Group.
    Pediatr Infect Dis J; 2008 Oct; 27(10):870-3. PubMed ID: 18776822
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants.
    Singleton R, Dooley L, Bruden D, Raelson S, Butler JC.
    Pediatr Infect Dis J; 2003 Jun; 22(6):540-5. PubMed ID: 12799511
    [Abstract] [Full Text] [Related]

  • 53. Respiratory syncytial virus infections in congenital heart defects--hospitalizations and costs.
    Meberg A, Bruu AL.
    Acta Paediatr; 2006 Apr; 95(4):404-6. PubMed ID: 16720485
    [Abstract] [Full Text] [Related]

  • 54. Palivizumab efficacy in preterm infants with gestational age < or = 30 weeks without bronchopulmonary dysplasia.
    Grimaldi M, Gouyon B, Sagot P, Quantin C, Huet F, Gouyon JB, Burgundy Perinatal Network.
    Pediatr Pulmonol; 2007 Mar; 42(3):189-92. PubMed ID: 17243184
    [Abstract] [Full Text] [Related]

  • 55. Passive immunisation against respiratory syncytial virus: a cost-effectiveness analysis.
    Rietveld E, Steyerberg EW, Polder JJ, Veeze HJ, Vergouwe Y, Huysman MW, de Groot R, Moll HA.
    Arch Dis Child; 2010 Jul; 95(7):493-8. PubMed ID: 20504841
    [Abstract] [Full Text] [Related]

  • 56. Cost effectiveness of palivizumab for RSV prevention in high-risk children in the Netherlands.
    Nuijten M, Lebmeier M, Wittenberg W.
    J Med Econ; 2009 Jul; 12(4):291-300. PubMed ID: 19811111
    [Abstract] [Full Text] [Related]

  • 57. Recommendations for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease.
    Tulloh R, Marsh M, Blackburn M, Casey F, Lenney W, Weller P, Keeton BR, Working Group of the British Paediatric Cardiac Association.
    Cardiol Young; 2003 Oct; 13(5):420-3. PubMed ID: 14694935
    [Abstract] [Full Text] [Related]

  • 58. Use of palivizumab to control an outbreak of syncytial respiratory virus in a neonatal intensive care unit.
    Abadesso C, Almeida HI, Virella D, Carreiro MH, Machado MC.
    J Hosp Infect; 2004 Sep; 58(1):38-41. PubMed ID: 15350712
    [Abstract] [Full Text] [Related]

  • 59. Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients.
    Chávez-Bueno S, Mejías A, Merryman RA, Ahmad N, Jafri HS, Ramilo O.
    Pediatr Infect Dis J; 2007 Dec; 26(12):1089-93. PubMed ID: 18043443
    [Abstract] [Full Text] [Related]

  • 60. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.
    Reeve CA, Whitehall JS, Buettner PG, Norton R, Reeve DM, Francis F.
    J Paediatr Child Health; 2006 May; 42(5):253-8. PubMed ID: 16712554
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.